TBI:NYSETrueBlue, Inc. Analysis

TrueBlue, Inc. (TBI) is trading at $5.84, comfortably above its 20‑day ($4.45) and 50‑day ($4.07) SMAs and just under its 200‑day SMA ($5.13), indicating short‑term strength but a still‑neutral longer trend. The stock is deep in overbought territory (RSI 80) while the MACD remains bullish, suggesting momentum could stall pending the Q1 2026 earnings release. Revenue grew 8.3% YoY to $1.62 B, driven by skilled‑trade and energy placements, yet margins remain thin (gross 22.6%, operating –3.4%) and cash flow is negative, with a sizable debt load ($124 M) and a historic max drawdown of ‑57%. Valuation appears attractive – forward PE 10.6 versus an industry average of 30.9, P/B 0.64 and price‑to‑sales 0.11 – but the balance sheet stress and high 30‑day volatility (≈79%) raise caution.
The consensus analyst view is a “buy” with a target price of $7.75, implying roughly 32% upside. Upcoming earnings and the newly appointed independent director could provide catalysts, but investors should monitor the overbought RSI, the proximity of resistance at $6.09, and the company’s ability to convert revenue growth into sustainable profitability.